Sage Journals: Discover world-class research

Abstract

Purpose

Exemestane, a steroidal aromatase inhibitor, is an important therapeutic option in the treatment of post-menopausal hormone receptor positive breast cancer. Adverse effects include hot flashes and bone loss, but rarely is hepatotoxicity reported. We report a case of exemestane induced cholestatic liver injury following exemestane initiation.

Case report

A now 77-year-old Caucasian female with primary biliary cirrhosis (PBC), and metastatic hormone receptor positive breast cancer originally diagnosed in 2000 who developed symptoms of pruritus, diarrhea, grade 2 transaminitis, and grade 1 hyperbilirubinemia three weeks after exemestane initiation.

Management and outcome: Due to the patient’s signs and symptoms, exemestane was discontinued and the patient was continued on cholestyramine until resolution of her laboratory abnormalities. Approximately a week after discontinuation, the patient was started and maintained on anastrozole without recurrence of her symptoms.

Discussion

Hepatotoxicity with aromatase inhibitors have rarely been reported in clinical trials and to date, instances of exemestane induced hepatotoxicity has only been reported in two case reports. The patient’s history of primary biliary cirrhosis may be an important risk factor for the development of hepatotoxicity from exemestane.

Get full access to this article

View all access options for this article.

References

Waks

Winer

EP.

Breast cancer treatment: a review. JAMA 2019; 321: 288–300.

Boon

Chow

Simpson

ER.

The multiple roles of estrogens and the enzyme aromatase. Prog Brain Res 2010; 181: 209–232.

Grodin

Siiteri

Macdonald

PC.

Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973; 36: 207–214.

Garreau

Delamelena

Walts

, et al. Side effects of aromatase inhibitors versus tamoxifen: the patients’ perspective. Am J Surg 2006; 192: 496–498.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Exemestane. Micromedex solutions. Truven Health Analytics, http://micromedex.com/ (updated 30 June 2020; accessed 7 August 2020).

Coombes

Hall

Gibson

, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081–1092.

Goss

Ingle

Alés-Martínez

, et al.; NCIC CTG MAP.3 Study Investigators. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011; 364: 2381–2391.

Howell

Cuzick

Baum

, et al.; ATAC Trialists’ Group. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60–62.

10.

Thürlimann

Keshaviah

Coates

, et al.; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747–2757.

11.

Goss

Ingle

Pritchard

, et al. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27 – a randomized controlled phase III trial. J Clin Oncol 2013; 31: 1398–1404.

12.

De Placido

Gallo

De Laurentiis

, et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol 2018; 19: 474–485.

13.

Pfizer, Aromasin (exemestane tablets) package insert, 2007.

14.

AstraZeneca, ARIMIDEX (anastrozole tablets) package insert, 2005.

15.

Novartis

(letrozole tablets) package insert, 2004.

16.

Purohit

Cappell

MS.

Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol 2015; 7: 926–941.

17.

Beukers

De Rave

Van den Berg

, et al. Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases. Aliment Pharmacol Ther 1992; 6: 459–468.

18.

Jorquera

Almar

Linares

, et al. Antipyrine clearance and metabolite formation in primary biliary cirrhosis. Dig Dis Sci 2001; 46: 352–359.

19.

Lelouët

Bechtel

Paintaud

, et al. Caffeine metabolism in a group of 67 patients with primary biliary cirrhosis. Int J Clin Pharmacol Ther 2001; 39: 25–32.

20.

Kamdem

Flockhart

Desta

In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos 2011; 39: 98–105.

21.

Johannessen

Engan

Di Salle

, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997; 3: 1101–1108.

22.

Bohn Sarmiento

Aguiar Bujanda

Aguiar Morales

, et al. Toxic hepatitis secondary to oral administration of exemestane. Rev Oncol 2003; 5: 550–551.

23.

Bao

Fetting

Mumford

, et al. Severe prolonged cholestatic hepatitis caused by exemestane. Breast Cancer Res Treat 2010; 121: 789–791.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.18 MB

Exemestane induced cholestatic liver injury – A case report